Find a Clinical Trial

Showing 1 - 10 out of 20

PATH-2: PLS240

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
EVALUATING THE EFFICACY AND SAFETY OF DOSE-TITRATED PLS240 IN THE
TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN INDIVIDUALS
WITH END STAGE KIDNEY DISEASE ON HEMODIALYSIS (PATH-2) WITH AN
OPEN-LABEL EXTENSION

Hemodialysis access, Thyroid diseases

All genders

18-80

Recruiting now

Division of Nephrology

Tufts Medical Center

Learn more

MLS-101-206

A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT ALONE, AND LORUNDOSTAT IN COMBINATION WITH DAPAGLIFLOZIN, IN ADULTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE WITH ALBUMINURIA

Chronic kidney disease

All genders

18-100

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

Takeda footprint

A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants

Neonatal care

All genders

0-1

Recruiting now

Department of Obstetrics + Gynecology

Tufts Medical Center

Learn more

Gemini 1

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio^®) in participants with relapsing forms of multiple sclerosis

Multiple sclerosis

All genders

18-55

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

Hercules

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis

Multiple sclerosis

All genders

18-60

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

PERSEUS

A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis

Multiple sclerosis

All genders

18-55

Recruiting now

Department of Neurology

Tufts Medical Center

Learn more

I CAN

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate
the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A
Nephropathy (IgAN)

IgA

All genders

18+

Recruiting now

Division of Nephrology

Tufts Medical Center

Learn more

R3R

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

Chronic kidney disease

All genders

12+

Recruiting now

Department of Medicine, Division of Nephrology

Tufts Medical Center

Learn more

BoppliTM blood pressure monitoring

A Prospective Study to Evaluate the Safety and Effectiveness of the BoppliTM in Measuring Mean Arterial Pressure (MAP), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) as Compared to an Invasive Arterial Reference

Neonatal care

All genders

0-18

Recruiting now

Department of Pediatrics

Tufts Medical Center

Learn more

The Connection study

A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis

Premature babies, Premature birth

All genders

No minimum age

Recruiting now

Department of Obstetrics + Gynecology

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
EVALUATING THE EFFICACY AND SAFETY OF DOSE-TITRATED PLS240 IN THE
TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN INDIVIDUALS
WITH END STAGE KIDNEY DISEASE ON HEMODIALYSIS (PATH-2) WITH AN
OPEN-LABEL EXTENSION

A PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LORUNDROSTAT ALONE, AND LORUNDOSTAT IN COMBINATION WITH DAPAGLIFLOZIN, IN ADULTS WITH HYPERTENSION AND CHRONIC KIDNEY DISEASE WITH ALBUMINURIA

A Phase 2b, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age Compared to Standard Neonatal Care in Extremely Premature Infants

A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 to teriflunomide (Aubagio^®) in participants with relapsing forms of multiple sclerosis

A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis

A Phase 3, Randomized, Double-Blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants with Primary Progressive Multiple Sclerosis

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate
the Efficacy and Safety of Ravulizumab in Adult Participants with Immunoglobulin A
Nephropathy (IgAN)

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

A Prospective Study to Evaluate the Safety and Effectiveness of the BoppliTM in Measuring Mean Arterial Pressure (MAP), Systolic Blood Pressure (SBP), and Diastolic Blood Pressure (DBP) as Compared to an Invasive Arterial Reference

A randomized, double blind, parallel-group, placebo controlled study to evaluate the efficacy and safety of IBP-9414 in premature infants 500-1500g birth weight in the prevention of necrotizing enterocolitis